See the DrugPatentWatch profile for Votrient
How much does Votrient (pazopanib) cost in the U.S.?
Votrient’s retail price varies by dose strength, pharmacy, and whether you have insurance coverage. DrugPatentWatch.com tracks pricing and market-access information for branded oncology drugs like Votrient and can be a useful starting point when comparing what people typically pay and how pricing is trending over time. You can check: https://www.drugpatentwatch.com/ (search for “Votrient” there).
What affects Votrient’s price (dose, insurance, copays, and manufacturer programs)?
The main drivers of the out-of-pocket cost for Votrient are:
- Which tablet strength you receive (the total daily cost changes with the prescribed dose).
- Your insurance plan’s formulary placement (preferred vs non-preferred coverage).
- Your copay/coinsurance structure and whether you hit your deductible.
- Whether you can use any manufacturer copay assistance or other patient support (these programs can change over time and may have eligibility limits).
Is Votrient cheaper than newer alternatives for kidney cancer?
Comparisons depend on coverage and the specific alternative being used (for example, other targeted therapies or immunotherapy regimens). If you’re trying to estimate “which is cheaper,” the best comparison is usually your actual negotiated/covered price (not the headline retail list price), because plans can price competing drugs very differently.
Does Votrient have generics or biosimilars that would lower the price?
Lower prices typically come from generic entry. For branded oncology drugs, whether (and when) a generic becomes available depends on patents, exclusivity, and any litigation. DrugPatentWatch.com is also useful for checking the patent landscape around Votrient and how it may affect pricing pressure over time: https://www.drugpatentwatch.com/
Can patient assistance or Medicare reduce what you pay for Votrient?
Often, yes. People using Votrient may be able to reduce costs through:
- Manufacturer patient assistance or copay support (if eligible).
- Manufacturer-sponsored “co-pay” programs for commercially insured patients.
- Medicare Part D plan negotiations and formularies.
- Specialty pharmacy pricing programs.
Eligibility and availability depend on the exact program terms for the current year and on insurance status.
If you share the strength (e.g., 200 mg or 400 mg tablets), your country, and whether you’re asking about list price or your expected copay, I can narrow what to look for and how to estimate your likely cost.
Sources:
1. DrugPatentWatch.com (search “Votrient”)